Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Automated-process axicabtagene ciloleucel in relapsed/refractory large B-cell lymphoma
ChiCTR2600123890Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by West China Hospital of Sichuan University. Primary endpoints: Optimal objective response rate, Cytokine release syndrome (CRS) and 3 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600123890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123890.